Replies to post #99619 on Biotech Values

[zipjet]

I think the current economy and the drive to reduce health care costs will be beneficial to m-enox and it could capture a substantial portion of the lovenox market.

IF I have this right the hospitals will be getting paid on DRG's many times when they will be using L. It makes no sense in that situation to NOT use mL at a discount. It immediately improves margins.

I think someone said that 75% of the L usage was in the hospital setting. The shift will happen as fast as the product can be put in the hospitals and staff can get accustomed to the change.

ij